WOBURN, Mass. & MIAMI– Comera Life Sciences, Inc. (“Comera”), which is developing a new generation of bio-innovative biologic medicines to improve patient access, safety, and convenience, and OTR Acquisition Corp. (Nasdaq: OTRA) (“OTR”), a publicly traded special purpose acquisition company (SPAC), today announced that the Securities and Exchange Commission (“SEC”) has declared the Registration Statement on Form S-4 filed in connection with the proposed business combination between the two companies, to be effective.
A special meeting of OTR stockholders (the “Special Meeting”) to approve, among other things, the proposed business combination, will be held in virtual format on May 10, 2022 at 2:00 p.m. Eastern Time. OTR also announced today that a definitive proxy statement/prospectus relating to the Special Meeting will be filed with the SEC on or about April 15, 2022, and will be mailed on or about April 15, 2022 to OTR’s stockholders of record as of the close of business on April 11, 2022.
Leading a compassionate new era in medicine, Comera Life Sciences is applying a deep knowledge of formulation science and technology to transform essential biologic medicines from intravenous (IV) to subcutaneous (SQ) forms. The goal of this approach is to provide patients with the freedom of self-injectable care, reduce institutional dependency and to put patients at the center of their treatment regimen.
